A carregar...
‘Precision medicine’ and ischaemic heart disease: the stage is set for the new antibody based therapies (lipid lowering and anti-inflammatory)
Improving cardiovascular risk assessment requires a ‘personalized’ approach. Appraisal of well-known cardiovascular risk factors should be integrated with markers of cardiovascular risk such as LDL cholesterol (C-LDL) and C-reactive protein (CRP). Results of the recent trials of PCSK9 inhibitor mono...
Na minha lista:
| Publicado no: | Eur Heart J Suppl |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439940/ https://ncbi.nlm.nih.gov/pubmed/30948956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/suz029 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|